parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.44 (overall 0.28)	0.44
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in salivary acinar cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 473	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 1382

receipt 1390: ETV1 in dopamine neurons, braak

power: full sample +0.13 (p 0.603, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.633, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.640, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.27, sign flips 0; without severely affected donors +0.13 (p 0.603, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ETV1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 1389: ETV1 in oligodendrocytes, braak

power: full sample -0.19 (p 0.439, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.19 (p 0.439, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.12 (p 0.627, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.09, sign flips 0; without severely affected donors -0.19 (p 0.439, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ETV1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts